Dermatology Therapeutic Pipeline Focuses on Innovation, States GBI Research in Its New Topical Report Recently Added at MarketPublishers.com
19 Jul 2017 • by Natalie Aster
LONDON – Today, there are more than 3,000 various dermatological conditions, ranging from rare autoimmune disorders like scleroderma, to very common conditions like atopic dermatitis and acne vulgaris. Dermatology is a highly diverse therapeutic area dealing with diseases of the skin, nails and hair. During the past decade, the majority of sectors of the therapeutic dermatology market has been highly genericized and saturated, and strongly dominated by small molecules. This market is characterised by considerable unmet need for safer and more efficacious treatments, as physicians usually cite poor efficacy, poor patient compliance and also problematic safety profiles.
Remarkable scientific advancements during the past decades have revealed a great number of new potential molecular targets, encouraging the advancement of a previously stagnant field. At present, the dermatology therapeutics pipeline encompasses 961 products, it is focusing on innovative biologic therapies. There is already a high degree of innovation in the dermatology therapy area, as there are 197 first-in-class pipeline products, many of these look rather promising in terms of efficacy and safety, and also carry lucrative potential to strengthen the treatment landscape for different dermatological conditions.
New topical report “Frontier Pharma: Dermatology - Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation” prepared by GBI Research examines the dermatology market, explores the dermatology therapeutic pipeline and also discusses how will pipeline innovation influence the future market development. This report offers in-depth insights into the commercial and clinical landscape of the dermatology market, provides vital data on the current unmet needs and touches upon the currently existing gaps in the market. Besides, this report includes a detailed analysis of the dermatology pipeline on the basis of stage of development, molecular target and molecule type. This report reviews the novel approaches to dermatological diseases treatment, evaluates the therapeutic potential of first-in-class targets, points out lucrative commercial opportunities in the dermatology market as well as gives access to important market data and future forecasts.
Visit the GBI Research catalogue to find many other topical research reports by this publisher.